Effect of valacyclovir on EHV-5 viral kinetics in horses with equine multinodular pulmonary fibrosis

Charlotte A. Easton-Jones, John E Madigan, Samantha Barnum, Lara K. Maxwell, Sandra D. Taylor, Terry Arnesen, Nicola Pusterla

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Equine herpesvirus-5 is commonly isolated from the lungs of horses with EMPF, suggesting an etiological link. Valacyclovir is used empirically to treat EMPF; however, no data is available concerning its impact on EHV-5 viral kinetics. Objectives: To determine the effect of oral administration of valacyclovir on EHV-5 viral load measured by qPCR in blood, nasal secretions (NS) and BALF in horses with EMPF. Animals: Six horses diagnosed with EMPF. Methods: A prospective clinical trial was performed. Horses received 10 days of PO administered valacyclovir (loading dose 30 mg/kg, maintenance dose 20 mg/kg). Blood, NS, and BALF were collected for EHV-5 viral kinetics analyses during treatment. Blood and NS were collected every other day. BALF was collected on day 0 and day 10. Results: There was no statistical difference in median EHV-5 viral load between day 0 and day 10 for all samples tested. In blood median EHV-5 viral load was 7676 (range 575-39 781) on day 0 and 6822 (range 1136-18 635) glycoprotein B (gB) gene copies per million cells on day 10. For NS median EHV-5 viral load was 2.944 × 106 (range 184 691-3.394 × 109) on day 0 and 8.803 × 106 (range 251 186-9.868 × 108) gB gene copies per million cells on day 10. For BALF median EHV-5 viral load was 59,842 (range 61-315 655) on day 0 and 185 083 (range 3562-542 417) gB gene copies per million cells on day 10. Conclusions and Clinical Importance: Valacyclovir might not be an effective short-term antiviral treatment but efficacy in treatment of EMPF is unknown.

Original languageEnglish (US)
Pages (from-to)1763-1767
Number of pages5
JournalJournal of Veterinary Internal Medicine
Volume32
Issue number5
DOIs
StatePublished - Sep 1 2018

Fingerprint

valacyclovir
Equid herpesvirus 5
Pulmonary Fibrosis
Viral Load
fibrosis
Horses
Nose
lungs
horses
kinetics
viral load
Glycoproteins
secretion
glycoproteins
blood
Genes
Herpesviridae
Antiviral Agents
Oral Administration
genes

Keywords

  • anti-viral drugs
  • herpesvirus
  • interstitial pneumonia
  • qPCR

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Effect of valacyclovir on EHV-5 viral kinetics in horses with equine multinodular pulmonary fibrosis. / Easton-Jones, Charlotte A.; Madigan, John E; Barnum, Samantha; Maxwell, Lara K.; Taylor, Sandra D.; Arnesen, Terry; Pusterla, Nicola.

In: Journal of Veterinary Internal Medicine, Vol. 32, No. 5, 01.09.2018, p. 1763-1767.

Research output: Contribution to journalArticle

Easton-Jones, Charlotte A. ; Madigan, John E ; Barnum, Samantha ; Maxwell, Lara K. ; Taylor, Sandra D. ; Arnesen, Terry ; Pusterla, Nicola. / Effect of valacyclovir on EHV-5 viral kinetics in horses with equine multinodular pulmonary fibrosis. In: Journal of Veterinary Internal Medicine. 2018 ; Vol. 32, No. 5. pp. 1763-1767.
@article{c07cb8468882459db01dc93d7975256b,
title = "Effect of valacyclovir on EHV-5 viral kinetics in horses with equine multinodular pulmonary fibrosis",
abstract = "Background: Equine herpesvirus-5 is commonly isolated from the lungs of horses with EMPF, suggesting an etiological link. Valacyclovir is used empirically to treat EMPF; however, no data is available concerning its impact on EHV-5 viral kinetics. Objectives: To determine the effect of oral administration of valacyclovir on EHV-5 viral load measured by qPCR in blood, nasal secretions (NS) and BALF in horses with EMPF. Animals: Six horses diagnosed with EMPF. Methods: A prospective clinical trial was performed. Horses received 10 days of PO administered valacyclovir (loading dose 30 mg/kg, maintenance dose 20 mg/kg). Blood, NS, and BALF were collected for EHV-5 viral kinetics analyses during treatment. Blood and NS were collected every other day. BALF was collected on day 0 and day 10. Results: There was no statistical difference in median EHV-5 viral load between day 0 and day 10 for all samples tested. In blood median EHV-5 viral load was 7676 (range 575-39 781) on day 0 and 6822 (range 1136-18 635) glycoprotein B (gB) gene copies per million cells on day 10. For NS median EHV-5 viral load was 2.944 × 106 (range 184 691-3.394 × 109) on day 0 and 8.803 × 106 (range 251 186-9.868 × 108) gB gene copies per million cells on day 10. For BALF median EHV-5 viral load was 59,842 (range 61-315 655) on day 0 and 185 083 (range 3562-542 417) gB gene copies per million cells on day 10. Conclusions and Clinical Importance: Valacyclovir might not be an effective short-term antiviral treatment but efficacy in treatment of EMPF is unknown.",
keywords = "anti-viral drugs, herpesvirus, interstitial pneumonia, qPCR",
author = "Easton-Jones, {Charlotte A.} and Madigan, {John E} and Samantha Barnum and Maxwell, {Lara K.} and Taylor, {Sandra D.} and Terry Arnesen and Nicola Pusterla",
year = "2018",
month = "9",
day = "1",
doi = "10.1111/jvim.15230",
language = "English (US)",
volume = "32",
pages = "1763--1767",
journal = "Journal of Veterinary Internal Medicine",
issn = "0891-6640",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Effect of valacyclovir on EHV-5 viral kinetics in horses with equine multinodular pulmonary fibrosis

AU - Easton-Jones, Charlotte A.

AU - Madigan, John E

AU - Barnum, Samantha

AU - Maxwell, Lara K.

AU - Taylor, Sandra D.

AU - Arnesen, Terry

AU - Pusterla, Nicola

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Background: Equine herpesvirus-5 is commonly isolated from the lungs of horses with EMPF, suggesting an etiological link. Valacyclovir is used empirically to treat EMPF; however, no data is available concerning its impact on EHV-5 viral kinetics. Objectives: To determine the effect of oral administration of valacyclovir on EHV-5 viral load measured by qPCR in blood, nasal secretions (NS) and BALF in horses with EMPF. Animals: Six horses diagnosed with EMPF. Methods: A prospective clinical trial was performed. Horses received 10 days of PO administered valacyclovir (loading dose 30 mg/kg, maintenance dose 20 mg/kg). Blood, NS, and BALF were collected for EHV-5 viral kinetics analyses during treatment. Blood and NS were collected every other day. BALF was collected on day 0 and day 10. Results: There was no statistical difference in median EHV-5 viral load between day 0 and day 10 for all samples tested. In blood median EHV-5 viral load was 7676 (range 575-39 781) on day 0 and 6822 (range 1136-18 635) glycoprotein B (gB) gene copies per million cells on day 10. For NS median EHV-5 viral load was 2.944 × 106 (range 184 691-3.394 × 109) on day 0 and 8.803 × 106 (range 251 186-9.868 × 108) gB gene copies per million cells on day 10. For BALF median EHV-5 viral load was 59,842 (range 61-315 655) on day 0 and 185 083 (range 3562-542 417) gB gene copies per million cells on day 10. Conclusions and Clinical Importance: Valacyclovir might not be an effective short-term antiviral treatment but efficacy in treatment of EMPF is unknown.

AB - Background: Equine herpesvirus-5 is commonly isolated from the lungs of horses with EMPF, suggesting an etiological link. Valacyclovir is used empirically to treat EMPF; however, no data is available concerning its impact on EHV-5 viral kinetics. Objectives: To determine the effect of oral administration of valacyclovir on EHV-5 viral load measured by qPCR in blood, nasal secretions (NS) and BALF in horses with EMPF. Animals: Six horses diagnosed with EMPF. Methods: A prospective clinical trial was performed. Horses received 10 days of PO administered valacyclovir (loading dose 30 mg/kg, maintenance dose 20 mg/kg). Blood, NS, and BALF were collected for EHV-5 viral kinetics analyses during treatment. Blood and NS were collected every other day. BALF was collected on day 0 and day 10. Results: There was no statistical difference in median EHV-5 viral load between day 0 and day 10 for all samples tested. In blood median EHV-5 viral load was 7676 (range 575-39 781) on day 0 and 6822 (range 1136-18 635) glycoprotein B (gB) gene copies per million cells on day 10. For NS median EHV-5 viral load was 2.944 × 106 (range 184 691-3.394 × 109) on day 0 and 8.803 × 106 (range 251 186-9.868 × 108) gB gene copies per million cells on day 10. For BALF median EHV-5 viral load was 59,842 (range 61-315 655) on day 0 and 185 083 (range 3562-542 417) gB gene copies per million cells on day 10. Conclusions and Clinical Importance: Valacyclovir might not be an effective short-term antiviral treatment but efficacy in treatment of EMPF is unknown.

KW - anti-viral drugs

KW - herpesvirus

KW - interstitial pneumonia

KW - qPCR

UR - http://www.scopus.com/inward/record.url?scp=85053493542&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053493542&partnerID=8YFLogxK

U2 - 10.1111/jvim.15230

DO - 10.1111/jvim.15230

M3 - Article

C2 - 30221792

AN - SCOPUS:85053493542

VL - 32

SP - 1763

EP - 1767

JO - Journal of Veterinary Internal Medicine

JF - Journal of Veterinary Internal Medicine

SN - 0891-6640

IS - 5

ER -